StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ:EGRX opened at $1.49 on Friday. Eagle Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $6.37. The firm has a 50 day moving average of $1.05 and a 200 day moving average of $1.30.

Hedge Funds Weigh In On Eagle Pharmaceuticals

A number of large investors have recently made changes to their positions in EGRX. Jacobs Levy Equity Management Inc. acquired a new position in shares of Eagle Pharmaceuticals during the third quarter worth $453,000. RBF Capital LLC increased its position in shares of Eagle Pharmaceuticals by 11.7% during the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after purchasing an additional 14,991 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Eagle Pharmaceuticals during the third quarter worth $96,000. Finally, DGS Capital Management LLC increased its position in shares of Eagle Pharmaceuticals by 44.9% during the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares in the last quarter. 85.36% of the stock is owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.